Addex ends development of ADX10059 for chronic indications

Addex Pharmaceuticals Ltd said that it is ending development of its negative allosteric modulator, ADX10059, for chronic indications including long-term treatment of gastroesophageal reflux disease (GERD) and migraine prophylaxis.